“And when you compound something like that, you don’t really know what the functional concentration of the products is. Nor do you know how well those products are suspended, dissolved or carried in the vehicle and how well they are released in the skin.”
Although many people have used these kinds of compounded products, many of which work fairly well, it’s important to use officially studied compounded products that have been rigorously designed and manufactured, he says.
“Such products have been studied to show that the ingredients in the vehicle in fact are effective, and that the vehicle plus the two active ingredients works better than any of the individual active ingredients,” notes Dr. Pariser. “The only way you can know that is through clinical trials.”
Halobetasol-tazarotene lotion represents a relatively new combination. As with betamethasone-calcipotriene, both ingredients have demonstrated efficacy and earned approvals in psoriasis both separately and together.
“But this new combination product has the advantage of a vehicle that has been tested and proven effective where both of the active ingredients are equally therapeutic in this new vehicle,” he says.
Dr. Pariser is a current or previous investigator and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, Merck, Novartis, Ortho Dermatologics, Pfizer, Promius and Sun Pharma.
David M Pariser MD. “Combination Therapy in Managing Psoriasis Patients.” South Beach Symposium. February 8, 2020.